Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2020-05-19 Regulatory Filings
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Agreement with Freeman Rd & PHI Group - Pilots in Australia 3 pages 124.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 May 2020 regarding a cooperation agreement between HeraMED Limited and Freeman Road and PHI group to initiate pilots and clinical studies in Australia. It details the terms of the agreement, the clinical study design, and commercial considerations such as options granted upon milestones. The document is an announcement of a new operational and commercial development related to clinical studies and partnerships, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a general regulatory announcement category as it informs the market about a material business development. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-05-19 English
Exclusive Agreement Executed with Australian Distributor 3 pages 141.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 8 May 2020, detailing a new exclusive distribution agreement between HeraMED Limited and Advanced Pregnancy Solutions (APS) for the HeraCARE platform in Australia and New Zealand. The content focuses on the terms of the distribution agreement, strategic business development, and market opportunity due to COVID-19. There are no financial statements, quarterly or annual results, audit information, or regulatory certifications included. The document is a corporate announcement about a capital/financing-related business development (distribution agreement to accelerate commercialisation and growth). It is not a report, earnings release, or management discussion. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9390 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2020-05-07 English
Quarterly Activities and CashFlow Report 8 pages 251.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 April 2020 providing a quarterly update on HeraMED Limited's progress for the three months ending 31 March 2020 (Q1 FY20). It includes operational highlights, clinical study updates, market strategy, COVID-19 impact, and a financial overview with detailed cash flow data. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for ASX-listed entities, confirms this is a quarterly report containing substantive financial data and analysis for a period shorter than a full fiscal year. The document is approximately 15,000 characters long and contains actual financial statements and detailed operational commentary, fitting the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q1 2020
2020-04-30 English
New FDA Recommendations - Fetal & Maternal Monitoring 2 pages 172.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 February 2020 from HeraMED Limited regarding new FDA recommendations for fetal and maternal monitors during COVID-19. It discusses updated FDA guidance and its impact on the company's product, HeraBEAT, including commercial and operational implications. The document is an announcement of regulatory guidance and company strategy rather than a financial report, earnings release, or detailed management discussion. It does not contain financial statements, voting results, or executive changes. The content fits best as a general regulatory announcement about FDA guidance and company response, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-26 English
Appendix 2A & Cleansing Notice 16 pages 322.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A' and is an 'Application for quotation of securities' submitted to the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and the purpose of the issue. The document is a formal application form related to the listing or quotation of new securities on the exchange. It is not a financial report, earnings release, management discussion, or any other type of report. It is also not a simple announcement or notification but a regulatory form required for the quotation of securities. This type of document corresponds to a Share Issue/Capital Change announcement, as it deals with the issuance and quotation of new securities.
2020-04-16 English
US Market Strategy Presentation - April 2020 34 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is titled 'US Market Presentation | April 2020' and contains detailed information about HeraMED's US market strategy, digital transformation in maternity care, healthcare challenges, cost savings, and strategic targeting of providers and payers. It includes forward-looking statements, market data, and strategic insights. There is no indication that this is a regulatory filing, financial report, earnings release, or legal proceeding. The content is consistent with a presentation aimed at investors or stakeholders to explain the company's market approach and business model. The length is substantial (15,000 characters), and the document is proprietary and confidential, typical of investor presentations. Therefore, the document best fits the category of an Investor Presentation (IP).
2020-04-06 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.